Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Safety and Effectiveness of the Optilume® BPH Catheter System in a Post-Market Study

NCT: NCT06312722 · RECRUITING

NCT IDNCT06312722
StatusRECRUITING
Start Date2024-02-07
Completion2031-02-07
SponsorUrotronic Inc. (INDUSTRY)
First posted
Last updated

Brief Summary

The goal of this clinical trial is to verify the continued safety and effectiveness for the Optilume BPH Catheter System.

Frequently Asked Questions

What is Safety and Effectiveness of the Optilume® BPH Catheter System in a Post-Market Study?

Safety and Effectiveness of the Optilume® BPH Catheter System in a Post-Market Study is a clinical trial registered under NCT06312722. Current status: RECRUITING.

What is the status of NCT06312722?

The current status of NCT06312722 (Safety and Effectiveness of the Optilume® BPH Catheter System in a Post-Market Study) is: RECRUITING.

When did Safety and Effectiveness of the Optilume® BPH Catheter System in a Post-Market Study start?

Safety and Effectiveness of the Optilume® BPH Catheter System in a Post-Market Study started on 2024-02-07.

Related Devices

K191061Optilume Basic Urological Balloon Dilation CatheterUrotronic, Inc. K250910Optilume® High Pressure Urological Balloon Dilation CatheterUrotronic, Inc. PMA P210020Catheter, Balloon, Urethral, Drug-CoatedUrotronic, Inc. PMA P220029Drug coated prostatic dilation catheter for benign prostatic hyperplasiaUrotronic, Inc.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑